CNTA - Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc
1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom
44 203 9206789
https://www.centessa.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 82
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | CEO & Director | 957.67k | N/A | 1977 |
| Dr. Gregory M. Weinhoff M.B.A., M.D., MBA | Principal Accounting Officer & CFO | 655k | N/A | 1971 |
| Dr. David M. Chao Ph.D. | Chief Admin. Officer | 655k | N/A | 1968 |
| Ms. Kristen K. Sheppard Esq., J.D. | Sr. VP of Investor Relations & Corp. Communications | N/A | N/A | N/A |
| Mr. Iqbal J. Hussain L.L.B. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | N/A | N/A | 1981 |
| Ms. Karen M. Anderson | Chief People Officer | N/A | N/A | 1968 |
| Dr. Antoine Yver M.D., M.Sc., MSc | Exec. VP & Chairman of Devel. | N/A | N/A | 1958 |
| Ms. Tia L. Bush | Chief Quality Officer | N/A | N/A | 1971 |
| Dr. David John Grainger Ph.D. | Chief Innovation Officer | N/A | N/A | 1969 |
| Dr. Harris L. Rotman Ph.D. | Sr. VP of Regulatory Affairs | N/A | N/A | N/A |
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Corporate governance
Centessa Pharmaceuticals plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
